Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia

Valery Leytin,1,2,3 Sergiy Mykhaylov,1 Alison F. Starkey,1,4 David J. Allen,1 Herbert Lau,1,3 Heyu Ni,1,2,3,4 John W. Semple,1,2,4,5 Alan H. Lazarus1,2,4,6 and John Freedman1,2,3,6
1Division of Transfusion Medicine, Department of Laboratory Medicine, St Michael’s Hospital, 2Toronto-Hamilton Platelet Immunobiology Group, 3Department of Laboratory Medicine and Pathobiology, University of Toronto, 4The Canadian Blood Services, 5Department of Pharmacology, University of Toronto, and 6Department of Medicine, University of Toronto, Toronto, ON, Canada

Summary

We have previously shown that injection of anti-glycoprotein (GP) IIb induces murine immune thrombocytopenia (ITP) and that intravenous immunoglobulin (IVIg) ameliorates ITP. We hypothesise that murine ITP may be associated with platelet apoptosis, which is upregulated by anti-GPIIb and downregulated by IVIg. The current study demonstrated that anti-GPIIb injection induced three critical apoptosis manifestations in platelets: (i) mitochondrial inner transmembrane potential (ΔΨm) depolarisation; (ii) caspase-3 activation; and (iii) phosphatidylserine (PS) exposure. IVIg administration inhibited caspase-3 activation and PS exposure, but not ΔΨm-depolarisation, in anti-GPIIb-treated platelets, demonstrating that IVIg ameliorates thrombocytopenia concomitantly with inhibiting late, but not early mechanisms of platelet apoptosis.

Keywords: murine model, immune thrombocytopenia, anti-glycoprotein IIb antibody, intravenous immunoglobulin, platelet apoptosis.

While intravenous immunoglobulin (IVIg) is used to treat immune thrombocytopenia (ITP) and other autoimmune diseases, its mechanism of action remain unclear. Several theories have been proposed, including the ability of IVIg to block the reticuloendothelial system (RES), an effect on the inhibitory FcγRIIB receptor, neutralisation by anti-idiotypic antibodies and modulation of cytokine cascades (Lazarus & Crow, 2003). An effect of IVIg on apoptosis of nucleated cells has been demonstrated both in vivo and in vitro; IVIg manifests anti-apoptotic or pro-apoptotic action depending on the targeted cell type (Prasad et al, 1998; Viard et al, 1998).

Over the last decade, apoptosis of anucleated cytoplasts and platelets has been recognised (Vanags et al, 1997; Wolf et al, 1999; Brown et al, 2000; Leytin & Freedman, 2003; Leytin et al, 2004). Platelet apoptosis has been documented in different models using well-defined apoptosis markers of nucleated cells (Budihardjo et al, 1999; Kroemer & Reed, 2000) such as depolarisation of the mitochondrial inner transmembrane potential (ΔΨm), Bcl-2 family proteins expression, caspase-3 activation and phosphatidylserine (PS) exposure (Leytin & Freedman, 2003). These data demonstrate that platelets contain the essential components for cytoplasmic apoptosis.

Many antiplatelet antibodies, notably anti-glycoprotein (GP) IIbIIIa and anti-GPIIb, induce ITP in humans and mice (Nieswandt et al, 2000). Some of these antibodies induce thrombocytopenia by targeting platelets through Fc receptors in the RES, while others act by Fc-independent mechanisms (Nieswandt et al, 2000). We have previously shown that profound thrombocytopenia induced in mice by injection of antiplatelet antibodies can be ameliorated by IVIg treatment.
Caspase-3 activation was measured by the cell-penetrating carboxyfluorescein-labelled fluoromethyl ketone tetrapeptide (FAM-DEVD-FMK; Chemicon International, Temecula, CA, USA) that specifically and covalently binds to active caspase-3 (Piguet & Vesin, 2002; Leytin et al, 2004). FAM-DEVD-FMK was dissolved in 50 μl of DMSO to create a 150x stock solution, according to the manufacturer’s recommendation, diluted (1:24) with PBS, pH 7.4, mixed by vortex and used immediately in caspase-3 activation assay. Aliquots (40 μl) of PRP were incubated in the dark for 1 h at 37°C with 10 μl of the 1:24 diluted FAM-DEVD-FMK solution, 450 μl of buffer A was added and samples were analysed by flow cytometry. Phosphatidylserine exposure on the platelet surface was determined by dual colour assay using concurrent staining of platelets with fluorescein isothiocyanate (FITC)-conjugated annexin V and phycoerythrin (PE)-conjugated hamster anti-mouse CD61 monoclonal antibody (BD Biosciences Pharmingen, San Diego, CA, USA). Aliquots (30 μl) of PRP, further diluted (1:6) with buffer A, were mixed with 10 μl of buffer A containing 8 mmol/l of CaCl₂ and incubated in the dark for 15 min at room temperature with a mixture of 2.5 μl annexin V-FITC and 2.5 μl anti-CD61-PE. Buffer A (300 μl) containing 2 mmol/l of CaCl₂ was then added and samples were analysed by flow cytometry using fluorescence-2 threshold to acquire platelet (CD61)-positive events (Leytin et al, 2004).

Results and discussion

Figure 1A shows that injection of anti-mouse GPIIb antibody induced marked thrombocytopenia in C57BL/6 mice, resulting in a drop of peripheral platelet count to 23.4 ± 1.9% of the mean value in untreated animals (P < 0.0001). Administration of non-immune IgG (used as a negative control for anti-GPIIb) did not induce thrombocytopenia. However, injection of 50 mg IVIg per mouse (equivalent to a dose of 2 g/kg body weight, used for ITP treatment in humans) significantly ameliorated anti-GPIIb-induced thrombocytopenia (P < 0.0001).

After injection of anti-GPIIb, platelets showed significantly higher caspase-3 activation (Fig 1B, P = 0.02), PS exposure (Fig 1C, P = 0.04) and ΔΨm depolarisation (Fig 2, P = 0.02). Treatment with IVIg ameliorated the anti-GPIIb-induced caspase-3 activation (P = 0.04) and PS exposure (P = 0.03) in the platelets (Fig 1B and C), but did not inhibit ΔΨm depolarisation (Fig 2, P = 0.42).

Two main pathways have been shown to lead to apoptosis in nucleated cells. The first, is the extrinsic pathway, which is initiated via the cell-surface death receptors, while the second is the intrinsic pathway, which is triggered by disruption of mitochondrial integrity including ΔΨm depolarisation. Activation of executioner caspase-3 and PS exposure are downstream of the extrinsic death signalling and intrinsic mitochondrial disintegration pathways (Budihardjo et al, 1999; Kroemer & Reed, 2000; Leytin & Freedman, 2003). Aberrant exposure of PS residues on the outer plasma membrane was shown to trigger mitochondrial damage, leading to caspase-3 activation and subsequent cell death.

Materials and methods

C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and treated as described in Fig 1. Blood from saphenous veins was collected into capillary tubes and 100 μl of blood was diluted in 900 μl of buffer A [145 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l MgCl₂, 5.6 mmol/l glucose, 0.1% bovine serum albumin (BSA), 10 mmol/l HEPES, pH 7.4], containing 0.42% sodium citrate.

The platelet count was determined in blood diluted (1:10) with buffer A, containing sodium citrate using a Coulter LH750 Analyzer (Beckman-Coulter, Miami, FL, USA). Platelet-rich plasma (PRP) was prepared by centrifugation of the final concentration of 1Æ5Æ6 mmol/l glucose, 0Æ6 mmol/l NaCl, 5Æ6 mmol/l KCl, 1Æ0 mmol/l MgCl₂, 1Æ0 mmol/l CaCl₂, 0Æ42% sodium citrate.

Depolarisation of ΔΨm was determined using the cell-penetrating lipophilic cationic fluorochrome JC-1 (Molecular Probes, Eugene, OR, USA) which accumulates in the mitochondrial matrix, driven by ΔΨm (Kroemer & Reed, 2000), and expressed as an increase of green-to-red (G/R) fluorescent ratio reflecting the decrease in content of JC-1 aggregates when the inner mitochondrial membrane becomes depolarised (Leytin et al, 2004). The JC-1 stock solution [2 mg/ml in dimethylsulphoxide (DMSO); Sigma Chemical Co., St Louis, MO, USA] was diluted with buffer B [phosphate-buffered saline (PBS; Sigma) supplemented with 1 mmol/l MgCl₂, 5.6 mmol/l glucose, 0.1% BSA, 10 mmol/l HEPES, pH 7.4] to a final concentration of 1 μg/ml, mixed by vortex, incubated in the dark for 15 min at room temperature and centrifuged for 15 min at 5996 g in 1Æ5 ml eppendorf tubes in an Eppendorf 5415C microfuge (Eppendorf, Westbury, NY, USA). The supernatants were harvested, combined and used immediately in the ΔΨm depolarisation assay as the JC-1 working solution. Aliquots (40 μl) of PRP were incubated in the dark for 45 min at 37°C with 460 μl of JC-1 working solution and samples were acquired on a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA).
membrane leaflet of nucleated cells allows for the phagocytic recognition and elimination of apoptotic cells (Budihardjo et al., 1999; Kroemer & Reed, 2000; Leytin & Freedman, 2003). In human platelets stimulated with calcium ionophore A23187, caspase-3 activation and PS exposure are also downstream of ΔΨm depolarisation (Leytin et al., 2004). The data presented in this study indicate that IVlg does not affect upstream breakdown of ΔΨm in platelets (Fig 2), but does inhibit downstream apoptotic events, caspase-3 activation (Fig 1B) and PS exposure (Fig 1C).
Nieswandt et al. (2000) demonstrated that the specificity of the target antigen recognised by antiplatelet antibodies determined the mechanism of phagocytic clearance of platelets in murine ITP. They have shown that ITP is induced by injection of intact anti-GPIIbIIIa monoclonal antibodies, but not F(ab)2 fragments, indicating Fc-dependent mechanism of platelet phagocytosis provoked by anti-GPIIbIIIa. In contrast, ITP induced by anti-GPIbα monoclonal antibodies is Fc-independent. Although several mechanisms have been proposed to explain the success of IVIg therapeutic treatment in ITP, the most accepted mechanism is the competitive inhibition of Fc receptors on phagocytic cells (reviewed by Lazarus & Crow, 2003). In a murine ITP model, we have shown that IVIg does not inhibit the binding of monoclonal anti-GPIIb to platelets both \emph{in vitro} and \emph{in vivo} (Crow et al., 2001). Taken together, these data suggest that: (i) platelet apoptosis induced by anti-GPIIb is an Fc-receptor-mediated process, i.e. a process dependent on the interactions of Fc fragments of anti-GPIIb antibodies with Fc receptors on phagocytic cells; and (ii) the suppressive effect of IVIg on anti-GPIIb-induced downstream events.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Administration of anti-glycoprotein (GP) IIb induces depolarisation of mitochondrial inner transmembrane potential (ΔΨ\textsubscript{m}) in mouse platelets, but intravenous immunoglobulin (IVIg) does not inhibit ΔΨ\textsubscript{m} depolarisation. Mice were either untreated or injected with non-immune IgG, anti-GPIIb or IVIg + anti-GPIIb as described in Fig 1. Platelet ΔΨ\textsubscript{m} depolarisation was determined using the JC-1 fluorescent probe. In the upper and middle panels, representative flow cytometric dot plots are shown and percentages of platelets containing high or low levels of JC-1 aggregates presented. In the lower panel, depolarisation of platelet ΔΨ\textsubscript{m} was quantified as the green-to-red (G/R) fluorescence ratio. Results of three independent experiments, each using two mice per group, are presented. Hence, mean ± SEM for six mice per group are shown and P-values between indicated groups were calculated by unpaired t-test; for 'no treatment' versus IgG-treatment groups, P = 0.41.}
\end{figure}
platelet apoptotic events is the result of inhibition of Fc fragment–Fc receptor interactions, rather than inhibition of anti-GPIIb binding to platelets.

In summary, we have shown that in vivo administration of an antibody against GPIIb is associated with apoptotic changes in mouse platelets characterised by the dissipation of mitochondrial transmembrane potential, activation of caspase-3 and exposure of PS. However, IVIg treatment significantly inhibited platelet caspase-3 activation and PS exposure. While the extent of the role played by apoptosis in the pathogenesis of ITP remains unknown, these results suggest a novel mechanism of IVIg action involving anti-apoptotic effects in platelets that may contribute to the amelioration of ITP.

Acknowledgements

This work was supported by a grant from the Bayer–Canadian Blood Services–Héma-Quebec–CIHR Partnership Fund.

References


